BioCentury
ARTICLE | Company News

Newer drugs lift Roche’s 1Q sales

April 19, 2019 7:25 PM UTC

Driven by newer drugs and expanded indications, Roche beat analyst expectations for its 1Q19 global pharmaceutical sales by 7% at CHF11.9 billion ($11.8 billion) vs. the Street's CHF11.2 billion ($11 billion) estimate. Pharmaceutical sales increased 10% at constant exchange rates (CER) from 1Q18.

Sales of multiple sclerosis drug Ocrevus ocrelizumab increased by 67% at CER to CHF836 million ($825.1 million) compared with 1Q18, beating consensus expectations of CHF725 million ($715.5 million). The European Commission approved the mAb against CD20 in January 2018; FDA approved the drug in March 2017 (see "Roche's Ocrevus Receives EU Approval for MS")...

BCIQ Company Profiles

Roche